[Comparative study of isosorbide dinitrates and mononitrates in patients with ischemic heart disease and stable angina pectoris caused by stenosing coronary atherosclerosis].
In an open clinical trial 19 patients with angina pectoris (functional class II-III) received in turn either non-retard tablets of isosorbide dinitrate (nitrosorbid, cardiket) in a mean dose 80 mg/day or isosorbide 5-mononitrate (mono mac) in a mean dose 51.5 mg/day. Each drug was given for a month. The effect was assessed by changes in frequency of anginal attacks and exercise tolerance. Non-retard isosorbide dinitrate and isosorbide 5-mononitrate demonstrate a good antiischemic effect, are safe and well tolerated. Isosorbide dinitrate and mononitrates do not differ significantly in reduction of the anginal attacks and by an increase in exercise tolerance but the effective dose of mono mac was 1.5-2 times less than that of nitrosorbide or cardiket, thus it is more cost-effective.
Lupanov
V P
VP
Alekseeva
I A
IA
Vasil'eva
N N
NN
Chotchaev
Kh Kh
KhKh
Naumov
V G
VG
D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy / Q000191:economics; D003324:Coronary Artery Disease / Q000150:complications* / Q000188:drug therapy / Q000191:economics*; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications* / Q000188:drug therapy / Q000191:economics*; D014665:Vasodilator Agents / Q000191:economics* / Q000627:therapeutic use
D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate